Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 ± Cetrelimab vs chemoradiotherapy in muscle-invasive bladder cancer
CTR20213299Phase 3Terminated
- Sponsor
- Janssen Research & Development
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine-releasing intravesical system in transitional cell carcinoma of the bladder (TCC), sponsored by Janssen Research & Development. Started Dec 2021; status: terminated.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on CTR20213299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213299.